Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | G6PD | P11413 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553196 | 0.80 | TAAR1 (0.45) | SLC6A4SLC6A3HRH3TAAR1 | |
| SCHEMBL21127861 | 0.76 | DAO (0.35) | CYP2C19SLC6A4SLC6A3ALDH1A1KDM4E | |
| SCHEMBL256012 | 0.75 | — | — | |
| SCHEMBL12748097 | 0.74 | ALDH1A1 (0.33) | ALDH1A1KDM4EMEN1POLBGAA | |
| SCHEMBL20680926 | 0.74 | KDM4E (0.38) | SLC6A4SLC6A3ALDH1A1KDM4EMEN1 | |
| SCHEMBL29953784 | 0.74 | PYCR1 (0.35) | HSP90AA1HSP90AB1CYP2C9CYP2C19PDK1 | |
| Ammonia Solution, Strong SCHEMBL2216424 | 0.73 | — | — | |
| SCHEMBL506596 | 0.72 | — | — | |
| SCHEMBL29955697 | 0.72 | HSP90AA1 (0.33) | HSP90AA1HSP90AB1CYP2C9CYP2C19PDK1 | |
| SCHEMBL10370548 | 0.71 | ALDH1A1 (0.32) | ALDH1A1KDM4EMEN1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47731-E1 | Kinase inhibitors and method of treating cancer with same | UNIV HEALTH NETWORK (CA) | 2019-11-19 | — | — | US | disclosed |
| US-RE47731-E1 | Kinase inhibitors and method of treating cancer with same | UNIV HEALTH NETWORK (CA) | 2019-11-19 | — | — | US | disclosed |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2019-07-23 | — | — | US | disclosed |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2019-07-23 | — | — | US | disclosed |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2018-10-04 | — | — | US | disclosed |
| US-9907800-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2018-03-06 | — | — | US | disclosed |
| US-9907800-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2018-03-06 | — | — | US | disclosed |
| US-9907800-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2018-03-06 | — | — | US | disclosed |
| US-20160045511-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2016-02-18 | — | — | US | disclosed |
| US-20160045511-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2016-02-18 | — | — | US | disclosed |
| EP-1682553-A1 | THIENOPYRAZOLES | Aventis Pharmaceuticals Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-6919335-B2 | Administering a therapeutically effective amount of a heterocyclic compound to the patient for the treatment of inosine monophosphate dehydrogenase associated disorders, such as allograft rejection | BRISTOL-MYERS SQUIBB CO. (US) | 2005-07-19 | — | — | US | disclosed |
| WO-2005026175-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| EP-1276739-A2 | HETEROCYCLES THAT ARE INHIBITORS OF IMPDH ENZYME | Bristol-Myers Squibb Company (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-04 | — | — | US | disclosed |
| WO-2001081340-A2 | HETEROCYCLES THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
| US-4777179-A | HISTAMINE H2-ANTAGONIST | GLAXO GROUP LIMITED (GB) | 1988-10-11 | — | — | US | disclosed |
| EP-0027744-B1 | THIOPHENE DERIVATIVES, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 1984-03-14 | — | — | EP | disclosed |
| US-4382929-A | HISTAMINE H2 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1983-05-10 | — | — | US | disclosed |
| EP-0027744-A1 | Thiophene derivatives, processes for the production thereof and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1981-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | XDH, IMPDH1, IMPDH2 | HSP90AA1 2655/4885HSP90AB1 2188/4885CYP2C9 388/4885 |
| US-20160045511-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | HSP90AA1 1243/4885HSP90AB1 1009/4885CYP2C9 1920/4885 |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | MAP3K6, MAP3K5, MAP3K19 | HSP90AA1 1243/4885HSP90AB1 1009/4885CYP2C9 1920/4885 |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | HSP90AA1 1243/4885HSP90AB1 1009/4885CYP2C9 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.